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BAFF Index and CXCL13 levels in the
cerebrospinal fluid associate respectively
with intrathecal IgG synthesis and cortical
atrophy in multiple sclerosis at clinical
onset
M. Puthenparampil1*, L. Federle1, S. Miante1, A. Zito1, E. Toffanin2, S. Ruggero2, M. Ermani2, S. Pravato2, D. Poggiali1,
P. Perini1, F. Rinaldi1 and P. Gallo1
Abstract
Background: B lymphocytes are thought to play a relevant role in multiple sclerosis (MS) pathology. The in vivo
analysis of intrathecally produced B cell-related cytokines may help to clarify the mechanisms of B cell recruitment
and immunoglobulin production within the central nervous system (CNS) in MS.
Methods: Paired cerebrospinal fluid (CSF) and serum specimens from 40 clinically isolated syndrome suggestive of
MS or early-onset relapsing-remitting MS patients (CIS/eRRMS) and 17 healthy controls (HC) were analyzed for the
intrathecal synthesis of IgG (quantitative formulae and IgG oligoclonal bands, IgGOB), CXCL13, BAFF, and IL-21.
3D-FLAIR, 3D-DIR, and 3D-T1 MRI sequences were applied to evaluate white matter (WM) and gray matter (GM)
lesions and global cortical thickness (gCTh).
Results: Compared to HC, CIS/eRRMS having IgGOB (IgGOB+, 26 patients) had higher intrathecal IgG indexes
(p < 0.01), lower values of BAFF Index (11.9 ± 6.1 vs 17.5 ± 5.2, p < 0.01), and higher CSF CXCL13 levels (27.7 ±
33.5 vs 0.9 ± 1.5, p < 0.005). In these patients, BAFF Index but not CSF CXCL13 levels inversely correlated with
the intrathecal IgG synthesis (r > 0.5 and p < 0.05 for all correlations). CSF leukocyte counts were significantly
higher in IgGOB+ compared to IgGOB− (p < 0.05) and HC (p < 0.01), and correlated to CSF CXCL13 concentrations
(r 0.77, p < 0.001).
The gCTh was significantly lower in patients with higher CSF CXCL13 levels (2.41 ± 0.1 vs 2.49 ± 0.1 mm, p < 0.05), while
no difference in MRI parameters of WM and GM pathology was observed between IgGOB+ and IgGOB−.
Conclusions: The intrathecal IgG synthesis inversely correlated with BAFF Index and showed no correlation with CSF
CXCL13. These findings seem to indicate that intrathecally synthesized IgG are produced by long-term PCs that have
entered the CNS from the peripheral blood, rather than produced by PCs developed in the meningeal follicle-like
structures (FLS). In this study, CXCL13 identifies a subgroup of MS patients characterized by higher leukocyte counts
in the CSF and early evidence of cortical thinning, further suggesting a role for this chemokine as a possible marker of
disease severity.
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Background
Several lines of evidence suggest that B cells play a cen-
tral role in the pathogenesis and/or the clinical evolution
of multiple sclerosis (MS). First, it is well known that the
great majority of MS patients have quantitative
(increased indexes) and/or qualitative (presence of IgG
oligoclonal bands, IgGOB) immunoglobulin changes in
the cerebrospinal fluid (CSF), indicating an intrathecal
Ig production [1, 2]. Second, histological studies have
disclosed the presence of complement deposition and
plasma cells (PCs) in white matter (WM) lesions [3].
Third, B cell follicle-like structures (FLS) are observed in
the meninges of patients with progressive MS [4] and
correlate with the degree of meningeal inflammation and
cortical demyelination, and with a higher rate of disabil-
ity progression [5]. Finally, the treatment of MS patients
with anti-CD20 monoclonal antibodies determines a
significant reduction in the number of both active brain
lesions and in clinical relapses [6–9].
The role of B cells in MS pathology may be multifa-
ceted [7]. Beside autoantibody production [10, 11], B
cells may present central nervous system (CNS) antigens
with co-stimulatory signals leading to activation and
proliferation of effector T cells, may produce pro-
inflammatory cytokines (e.g. IL-6, IL-12, and TNF), or
may regulate the immune response by providing IL-10, a
cytokine that suppresses the T cell functions either dir-
ectly or indirectly [12] (i.e., differentiation of T regula-
tory cells and the suppression of dendritic cell function
[7, 10–12]).
The presence of meningeal follicle-like structures
(FLS) has stimulated the hypothesis of a “germinal cen-
ter reaction” within the CNS of MS. Briefly, naïve B cells
recruited in the CNS (throughout CXCL13 signal) may
locally meet and present CNS antigens to T helper lym-
phocytes. Both B and T cells actively collaborate (re-
spectively as centroblast and follicular T helper, that
produce IL-21, the “signature” of an ongoing follicular
reaction) to establish a germinal center reaction that
leads B cell maturation to IgG-secreting PCs. PCs will
survive within the CNS thanks to intrathecally produced
B cell survival factors, such as B cell-activating factor
(BAFF), as suggested by a recent observation [13]. On
the other hand, we cannot exclude that FLS formation
may be a mere epiphenomenon of MS, expression of a
chronic meningeal inflammation, not directly involved
in intrathecal Ig synthesis.
We studied serum and CSF levels of soluble factors in-
volved in naïve B cell recruitment (CXCL13), in follicu-
lar reaction (IL-21) and intrathecal B cell survival
(BAFF) in MS patients at clinical onset and correlated
their intrathecal synthesis with local Ig production and
with magnetic resonance imaging (MRI) parameters of
white and gray matter damage. The aim of the study was
to explore whether, at clinical onset, B cell-related cyto-
kines could serve as immunological markers of MS
severity/prognosis.
Methods
Patients
Forty consecutive patients with a diagnosis of clinically
isolated syndrome suggestive of MS (CIS) or early-onset
relapsing-remitting MS (eRRMS), whose diagnosis was
achieved in agreement with the most recent diagnostic
criteria [14], were enrolled in the study. Inclusion criteria
were as follows: (i) age between 18 and 50 years, (ii) no
medical history of steroid therapy in the previous 30 days,
(iii) no medical history of immunomodulating or im-
munosuppressive therapy, and (iv) no gadolinium-
enhancing lesion at the MRI performed at the study entry.
Seventeen healthy controls (HC) were also enrolled in
the study. These subjects complained tension headache,
subjective transient sensory symptoms, psychosomatic
disorders, etc. that underwent lumbar puncture for diag-
nostic purposes having unexpected, subtle, but unspe-
cific white matter lesions at MRI. Immunological and
coagulation screenings, microbiological and standard
CSF analysis were normal; also upper aortic artery and
Transcranic ultrasound EcoColorDoppler and visual
evoked potentials were normal.
No differences for age and gender were observed
between eRRMS and HC (Table 1). The study was
Table 1 Standard serum and CSF parameters in HC and CIS/
eRRMS
HC CIS/eRRMS
Gender (F/M) 13/4 26/14
Age at LP (years) 43.2 ± 9.2 37.8 ± 10.0
Disease duration (years) n.a. 0.5 ± 0.9
CSF [Alb] (mg/dL) 17.0 ± 5.1 22.5 ± 9.8
Serum [Alb] (mg/dL) 4370.6 ± 379.0 4260.0 ± 333.6
QAlb (10
−3) 3.9 ± 1.2 5.3 ± 2.3*
CSF [IgG] (mg/dL) 2.2 ± 0.9 3.7 ± 1.8***
Serum [IgG] (mg/dL) 1141.2 ± 215.2 1042.0 ± 197.7
QIgG (10
−3) 1.9 ± 0.6 3.6 ± 1.7****
IgG Index 0.5 ± 0.1 0.7 ± 0.3***
IgG Loc (mg/dL) 0.1 ± 0.3 5.9 ± 10.2*
IgIF (%) 0 ± 0 11 ± 17*
IgGOB (%) 0% 65%****
Leukocyte counts (/μL) 2.1 ± 1.1 6.9 ± 7.7*
Disease duration was defined as the time between clinical disease onset and
lumbar puncture. For gander, IgIF% and IgGOB chi-square test was applied.
For all the other variables, a t test was performed
HC healthy controls, CIS/eRRMS CIS suggestive of MS or early RRMS, LP lumbar
puncture, n.a. not applicable, Csf cerebrospinal fluid, S serum, IgGOB IgG
oligoclonal bands
*p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001
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approved by the local ethics committee and a written
informed consent was obtained by all the participants.
CSF and serum routine analysis
CSF was collected by non-traumatic lumbar puncture
between 8:00 and 9:00 am. Routine examination on
paired CSF and serum specimens included cell count
and differentiation, CSF/serum IgG ratio (QIgG), CSF/
serum albumin ratio (QAlb) to estimate the integrity of
the blood-brain barrier (BBB), calculation of intrathecal
IgG synthesis by means of quantitative formulae (IgG
Index) [2] IgG Reiber’s Hyperbolic Function for IgG
intrathecal synthesis fraction (IgGIF) [1] and Local Pro-
duction (IgGLoc) [1], and demonstration of IgGOB by
isoelectric-focusing and specific IgG immunofixation.
BBB damage was considered when QAlb was higher than
the normal value for patient’s age (i.e., age/15 + 4). After
cell centrifugation, both CSF and serum were stored at
−80 °C until cytokine analysis.
Cytokine determination
CSF and serum levels of BAFF (R&D System, Cat.
Numb. DBLYS0B), IL-21 (Bender MedSystems Cat.
Numb. BMS2043TEN), and CXCL13 (R&D System, Cat.
Numb. DCX130) were measured by a highly sensitive
immune-enzymatic assay ELISA according to the manu-
facturer’s instruction. BAFF concentrations (pg/mL)
were measured on 1:2 diluted sera and on native CSF.
IL-21 and CXCL13 concentrations (pg/mL) were mea-
sured on native sera and CSF. Cytokine ratio (CSF/
serum cytokine: QBAFF, QCXCL13, and QIL-21) and Index
(CSF/serum cytokine/CSF/serum albumin: BAFF Index,
CXCL13 Index, IL21 Index) were calculated.
MRI protocol
Images were acquired using a 3T scanner (Ingenia,
Philips Medical Systems, Best, The Netherlands) with
33 mT/m power gradient and a 32-channel head coil.
No major hardware upgrades occurred during the study,
and bimonthly quality-assurance sessions assured meas-
urement stability. The following images were acquired
for each subject: (a) three-dimensional (3D) turbo field
echo (TFE, 3D-T1): repetition time (RT) 7.8 ms; echo
time (ET) 3.6 ms; 180 contiguous axial slices with the
off-center positioned on zero with thickness of 1.0 mm;
flip angle = 8°; matrix size = 220 × 220; FOV = 220 ×
220 × 180 mm3. This sequence was acquired before and
after gadolinium administration. (b) 3D-fluid attenuated
inversion recovery (FLAIR): RT 4800 ms; ET 310 ms; in-
version time (IT) 1650 ms; 365 contiguous axial slices
with thickness of 1.0 mm; matrix size 256 × 256; and
FOV = 256 × 256 × 182 mm3; (c) 3D-double inversion re-
covery (DIR): RT 13,000 ms, ET 10 ms, IT 3400/325 ms;
40 contiguous axial slices, resolution 1 × 1 × 3 mm, FOV
230 × 200 mm, time 3.5 min. Two experienced ob-
servers, blinded to the patient’s identity, assessed all im-
ages. The global cortical thickness (gCTh) was analyzed
by means of Freesurfer on 3D-T1 sequences. WM
lesions were identified on FLAIR sequences, while
cortical lesions (CL) were identified on DIR scans by
two blinded evaluators (PD, PS) using published con-
sensus recommendations.
Statistical analysis
For normally distributed variables, the T test (when two
groups were compared) or the ANOVA (for more than
two group comparisons) were performed applying the
Bonferroni correction. For ordinal categorical variables,
the Mann-Whitney U test was performed, while for no
ordinal variables, Pearson’s chi-square test was used.
Linear correlation between variables was tested using
Pearson’s single or multiple linear model when all vari-
ables were normally distributed. The significance level
was set at p < 0.05.
Results
Intrathecal IgG synthesis in HC and CIS/eRRMS
Table 1 summarizes routine serum and CSF findings in
HC and CIS/eRRMS. As expected, all the indexes of
intrathecal IgG synthesis (IgG CSF, QIgG, IgG Index,
IgGLoc, and IgGIF) were significantly higher in CIS/
eRRMS compared to HC. Higher QAlb values were ob-
served in CIS/eRRMS (5.3 ± 2.3 × 10−3) than in HC (3.9
± 1.2 × 10−3, p < 0.05), but only six CIS/eRRMS patients
(15 vs 0% in HC, p = 0.2) had BBB damage.
Intrathecal cytokine synthesis in HC and CIS/eRRMS
CXCL13
In HC, CXCL13 was found in all sera and, at very low
levels (0.9 ± 1.5 pg/mL), in 8/17 (47%) CSF. In these sub-
jects, no correlation was observed between QCXCL13 and
QAlb (r 0.2, p = 0.4), even when only CXCL13-positive
CSF were included in the analysis (r 0.7, p = 0.1). Since
these data indicated that CXCL13 was intrathecally pro-
duced, rather than derived from passive filtration from
blood, only the CSF concentrations of this cytokine were
considered in further analyses. CXCL13 was detected
more frequently (75%, p < 0.05) and at higher concentra-
tion (19.7 ± 29.3 pg/mL, p < 0.05) in the CSF of CIS/
eRRMS than HC.
IL-21
In HC, IL-21 was detectable in all CSF (28.1 ±
29.1 pg/mL) but only in one serum, thus suggesting
that CSF IL-21 was intrathecally produced. No difference
in CSF IL-21 levels was observed between HC (28.1 ±
29.1 pg/mL) and CIS/eRRMS (20.7 ± 22.8 pg/mL, p = 0.3).
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BAFF
BAFF was detected in all the sera and CSF of HC
and CIS/eRRMS. In HC QBAFF mildly correlated to
QAlb (r 0.4), indicating that CSF BAFF may result
from both choroid plexus filtration and active produc-
tion within the CNS. The BAFF Index was lower in
CIS/eRRMS (12.4 ± 5.5 pg/mL) than in HC (17.5 ±
5.2 pg/mL, p < 0.005).
IgGOB-based stratification of CIS/eRRMS
Based on the presence of IgGOB in the CSF, CIS/eRRMS
patients were divided in IgGOB positive (IgGOB+, 26
patients) and in IgGOB negative (IgGOB−, 14 patients)
(Table 2). The analysis based on this stratification dis-
closed that all the differences previously found between
HC and CIS/eRRMS were confirmed for IgGOB+
patients, but not for IgGOB− patients (Fig. 1a). Further-
more, serum IgG concentrations in IgGOB− were lower
than in HC (p < 0.01) and IgGOB+ (p < 0.05).
CSF CXCL13 concentrations were higher in IgGOB+
compared to both IgGOB− (p < 0.05) and HC (p < 0.005)
(Fig. 1b). A higher number of IgGOB+ patients had de-
tectable CXCL13 in the CSF (77%) compared to IgGOB−
(50%), but the difference was not significant (p = 0.2).
No difference in CSF IL-21 levels was observed
between HC, IgGOB−, and IgGOB+ (Fig. 1c).
As expected on the base of previous results, CSF
BAFF levels and Index were significantly lower in
IgGOB+ (50.7 ± 20.5 pg/ml, p < 0.05, and 11.9 ± 6.1,
both p < 0.005, respectively) but not in IgGOB− (69.9
± 27.3 pg/ml and 13.2 ± 5.1, respectively, p = 0.8 and
p = 0.1) compared to HC (Fig. 1d).
Correlation analysis
For the correlation analysis, only quantitative continu-
ous variables, namely IgG Index, IgGLoc, and IgGIF,
were included as dependent variables. Table 3 shows
the correlation between the parameters of intrathecal
IgG synthesis and BAFF Index or CSF CXCL13 con-
centrations in IgGOB+. CSF CXCL13 concentrations
correlated with all the parameters of intrathecal IgG
synthesis (Fig. 2a–c), while BAFF Index mildly corre-
lated only with IgGLoc values (Fig. 3a–c). In order to
avoid the influence of null values on the direct correl-
ation and considering that IgGOB+ presented null
values for CSF CXCL13, we focused on patients with
quantitatively increased intrathecal IgG synthesis. In
15 IgGOB+ patients having IgG Index, IgGLoc, and
IgGIF values above the normal range of reference,
only BAFF Index correlated to all these parameters
(Fig. 3a’–c’), while CXCL13 concentrations correlated
only with IgGLoc (Fig. 2a’).
Finally, BAFF Index did not correlate to CSF
CXCL13 concentrations in HC (r −0.36, p = 0.2), MS
patients (r −0.29, p = 0.1), IgGOB− (r −0.05, p = 0.9),
and IgGOB+ (r −0.31, p = 0.1).
CSF leukocyte counts in CIS/eRRMS and in IgGOB+ and
IgGOB−
CSF leukocyte number was significantly higher in
CIS/eRRMS (6.9 ± 7.7/μL) compared to HC (2.1 ±
1.1 μL, p < 0.05). CSF CXCL13 concentrations, but
not BAFF Index, significantly correlated to leukocyte
counts (r 0.77, p < 0.001, Table 4).
BOIgG+ had higher CSF leukocyte number (9.0 ±
8.6/μL) than IgGOB− (2.9 ± 2.4/μL, p < 0.05) and HC
(p < 0.01). In IgGOB+, CSF CXCL13 concentrations,
but not BAFF Index values, significantly correlated to
leukocyte number (r 0.77, p < 0.001, Table 4), while
no correlation between leukocyte number and all the
other CSF parameters was observed in BOIgG−.
MRI parameters in CIS/eRRMS
No difference in gCTh was observed between HC and
CIS/eRRMS. However, a higher variability in gCTh was
found in CIS/eRRMS (range 2.25–2.67 mm) compared
to HC (2.34–2.58 mm). In order to find associations
Table 2 Serum and CSF parameters in HC, IgGOB−, and IgGOB
+ patients
HC IgGOB− IgGOB+
Gender (F/M) 13/4 9/5 17/9
Age at LP (years) 43.2 ± 9.2 37.2 ± 10.7 38.2 ± 9.7
Disease duration
(years)
n.a. 0.3 ± 0.6 0.6 ± 1.1
Csf-[Alb] (mg/dL) 17.0 ± 5.1 21.2 ± 8.7 23.1 ± 10.4
S-[Alb] (mg/dL) 4370.6 ± 379.0 4225.0 ± 297.7 4278.8 ± 355.6
QAlb (10
−3) 3.9 ± 1.2 5.0 ± 2.0 5.4 ± 2.4*
Csf-[IgG] (mg/dL) 2.2 ± 0.9 2.4 ± 0.8 4.5 ± 1.8**** °°°°
S-[IgG] (mg/dL) 1141.2 ± 215.2 944.6 ± 124.2** 1094.3 ± 211.6°
QIgG (10
−3) 1.9 ± 0.6 2.6 ± 1.0 4.2 ± 1.8**** °°
IgG Index 0.5 ± 0.1 0.5 ± 0.1 0.8 ± 0.3**** °°°
IgG Loc (mg/dL) 0.1 ± 0.3 0.2 ± 0.6 9.0 ± 11.5** °
IgIF (%) 0 ± 0 1.1 ± 2.7 16.4 ± 18.5*** °°
Leukocyte counts (/μL) 2.1 ± 1.1 2.9 ± 2.4 9.0 ± 8.6*** °
Csf -[BAFF] (pg/mL) 67.3 ± 21.6 69.9 ± 27.3 50.7 ± 20.5* °
BAFF Index 17.5 ± 5.2 13.2 ± 5.1 11.9 ± 6.1**
Csf-[CXCL13] (pg/mL) 0.9 ± 1.5 5.0 ± 8.2 27.7 ± 33.5*** °
Csf-[IL21] (pg/mL) 28.1 ± 29.1 21.6 ± 25.3 20.2 ± 21.9
IgGOB+ patients differed from both BOIgG− and HC for intrathecal IgG
synthesis parameters, CSF CXCL13 concentrations, and BAFF Index values.
For gender, IgIF%, and IgGOB, chi square test was applied. For all the other
variables, a t test was performed. Abbreviations as in Table 1
P values compared to HC: *p < 0.5; **p < 0.01; ***p < 0.005; ****p < 0.001;
p values compared to IgGOB−: °p < 0.5; °°p < 0.01; °°°p < 0.005; °°°°p < 0.001
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between CSF (IgGOB detection, BAFF Index, CSF
CXCL13, IgG Index, IgGLoc, IgG IF) and MRI parame-
ters, we performed a subgroup analysis.
On the base CXCL13 concentrations in the CSF of
HC, we found a cutoff value of 6.8 pg/mL (μ + 4δ) that
allowed the identification of two groups of CIS/eRRMS
patients having CSF CXCL13 values below (CXCL13−,
20 patients) or above (CXCL13+, 20 patients) this limit.
All HC had CXCL13 values below this limit.
BAFF Index was not applicable in this analysis, since
its range did not differ between the two groups and
therefore a cut-off value was meaningless.
In as much as the three quantitative indexes of
intrathecal IgG synthesis gave highly concordant
values, only IgG Loc was considered for further ana-
lysis (values ≤0.0 = IgGLoc−; values >0.0 = IgGLoc+).
Interestingly, no difference in any MRI parameter was
observed between IgGOB+ and IgGOB− or between
IgGLoc− and IgGLoc+. CXCL13+ patients had a signifi-
cant thinning of gCTh (2.42 ± 0.09 mm) compared to
CXCL13− (2.48 ± 0.10 mm, p < 0.05; Fig. 4). The results
did not change when a different cut-off value (μ + 3δ,
i.e., 5.2 pg/mL) was applied.
No association was found between any CSF parame-
ters and WM or GM lesion number and volume.
Discussion
Intrathecally produced IgGOB can be demonstrated in the
great majority of MS patients at clinical onset, persist in the
CSF throughout the patient’s life, and constitute the major
evidence of B lymphocytes and PC involvement in MS
Fig. 1 IgG and cytokine concentrations in the CSF. IgG Loc expressed in mg/dL (a), CSF CXCL13 and IL-21 concentrations (pg/mL; b, c), and BAFF
Index values (d) in HC and CIS/eRRMS with (IgGOB+) or without (IgGOB−) intrathecal synthesis of IgG oligoclonal bands. IgGOB+ patients had
increased CXCL13, normal IL-21, and decreased BAFF Index compared to HC and IgGOB− patients. Only significant comparison is indicated.
Abbreviations: HC healthy controls, CIS/eRRMS CIS suggestive of MS or early RRMS, LP lumbar puncture, n.a. not applicable, CSF cerebrospinal fluid,
S serum. IgGOB+: patients with IgG oligoclonal bands in the CSF; IgGOB−: patients without IgG oligoclonal bands in the CSF
Table 3 Correlation between intrathecal IgG synthesis parameters
and BAFF Index or CXCL13
(A) All patients BAFF Index
IgG Loc (mg/dL) −0.41* 0.59***
IgIF (%) −0.36 0.45*
IgG Index −0.38 0.48*
(B) Only IS+ BAFF Index LCS-CXCL13
IgG Loc (mg/dL) −0.56* 0.57*
IgIF (%) −0.52* 0.35
IgG Index −0.64* 0.43
The correlation was calculating on overall population of BOIgG+ patients (A)
or including only patients with quantitatively increased intrathecal IgG
synthesis (IS+, B). R values derived from Pearson’s single linear model are
represented. Other abbreviations as in Table 2
*p < 0.5; **p < 0.01; ***p < 0.005
Puthenparampil et al. Journal of Neuroinflammation  (2017) 14:11 Page 5 of 9
pathology [3]. The origin of long-term secreting PCs, likely
the source of intrathecally synthesized IgG, has not been
established yet. Moreover, the progressive colonization of
MS meninges by FLS suggests that local B cell maturation
to PCs may support the intrathecal synthesis of IgM and
IgG [5]. However, since FLS accumulation seems to parallel
disease progression (i.e., they were demonstrated in high
percentage in progressive MS cases, rarely in RRMS and
not at clinical onset), we would expect to observe qualita-
tive modifications of the IgGOB patterns over the course of
the disease. On the contrary, longitudinal studies demon-
strated that IgGOB are almost qualitatively stable [15–19].
B cells have several other functions than producing
antibodies [12]. They may act as efficient antigen-
presenting or cytokine-secreting cells, thus enhancing
T cell response. Therefore, the pathogenic role of B
cells in the FLS may be multifaceted. FLS have been
observed in association with cortical inflammation, gray
matter demyelination, and various degrees of microglia
activation [4]. Moreover, meningeal and cortical inflam-
mation were found to correlate with some clinical
parameters, such as median age at disease onset, time
to disease progression, time to wheelchair dependence,
and age at death [4]. Thus, the analysis of intrathecally
synthesized B cell-related cytokines/chemokines may
give the opportunity to define the timing of B cell
recruitment and FLS formation in the CNS and to
explore the role of FLS in the pathogenesis and clinical
progression of MS.
In a previous study [13], we observed that BAFF Index
correlated to quantitative parameters of intrathecal IgG
synthesis in MS at clinical onset and suggested a BAFF-
dependent PCs survival within the CNS. In this study,
we analyzed the intrathecal production of cytokines
involved in B cell recruitment and follicular maturation
in order to explore the origin of intracerebral PCs.
Fig. 2 Correlations between CSF CXCL13 and intrathecal IgG synthesis. A mild correlation was observed between CSFCXCL13 and intrathecal
IgG synthesis when all the patients were included in the analysis (a–c). When the null values for intrathecal IgG synthesis were excluded, the
correlation was weak (a’) or lost (b’, c’)
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CXCL13, a chemokine that is not physiologically pro-
duced within the CNS, was increased in the CSF of CIS/
eRRMS, especially in IgGOB+ patients. This finding sug-
gests that CXCL13, produced by activated microgial
cells, becomes detectable since the early disease phases,
and is responsible for the recruitment of naïve B cells
within the CNS. On the other hand, BAFF, constitutively
produced in the CNS by astrocytes, is absorbed by local
antibody-producing PCs, thus explaining the decreased
levels of this cytokine in early MS stages. The previously
described increased BAFF levels in the CSF of progres-
sive MS [20] might found an explanation in the more
diffuse astroglial proliferation and in the decreased
burden of inflammation that characterize the more
advanced phase of MS. However, since CSF CXCL13
was detected, although rarely, in patients with no evi-
dence of intrathecal IgG synthesis, is not associated with
Fig. 3 Correlations between BAFF Index and intrathecal IgG synthesis. A mild correlation between BAFF Index and intrathecal IgG synthesis was
observed when all the patients were considered (a–c). The correlation was strong when the null values of intrathecal IgG synthesis were
excluded (a’–c’)
Table 4 Leukocyte counts in CIS/eRRMS correlates to
CSF-CXCL13
r r2 p value
CIS/eRRMS
CSF-[CXCL13] (pg/mL) 0.79 63.2% <0.001
BAFF Index −0.21 4.4% 0.2
IgGOB+
CSF-[CXCL13] (pg/mL) 0.77 59.3% <0.001
BAFF Index −0.22 4.7% 0.3
IgGOB−
Csf-[CXCL13] (pg/mL) 0.34 11.6% 0.3
BAFF Index 0.22 4.8% 0.5
Subgroup analysis revealed that this correlation was confirmed only in IgGOB+
patients. Abbreviations as in Table 2. R values derived from Pearson’s single
linear model are represented
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BAFF Index and correlates only mildly with IgGLoc, we
may argue that the majority of naïve B cells recruited in
the CNS do not undergo the process of maturation to
PCs. Taken all together, these findings do not speak in
favor of a germinal center reaction within FLS, at least
in early MS phases, and are in line with the qualitative
stability of IgGOB patterns during the course of MS.
An interesting finding of our study was the association
of CSF CXCL13, but not BAFF Index, with cortical thin-
ning since early MS phases. This observation seems to
link a soluble factor that plays a pivotal role in the B cell
recruitment in the CNS, to a MRI parameter of neuro-
degeneration (gray matter atrophy), that is correlated to
disability progression in MS.
Our findings are in line with the previous reports on
the association of CXCL13 to leukocyte CSF counts [20],
higher risk of relapse, and CIS conversion to MS [21], as
well as with higher disease activity in the WM [22, 23],
further suggesting a possible role of CXCL13 as a sol-
uble marker of disease activity or severity in MS.
Other cytokines were found to increase in MS CSF
[24]. Among these, the macrophage/microglia-derived
interleukin-1 beta (IL-1β) was also found to correlate
with cortical thinning [25]. The finding that both IL-1β
and CXCL13 can be found in the CSF of very early MS
and both factors associate with cortical thinning further
suggests a pivotal role of microglia in MS pathology.
Indeed, in vitro, CXCL13 is produced by monocytes, and
at much higher levels by macrophages, and CXCL13
mRNA and protein expression is induced by TNFα and
IL-1β [26]. All these data suggest that activated and
proliferating microglia cells (a characteristic histological
feature of cortical pathology) produce large amounts
cytokines, such as IL-1β and CXCL13, that attract and
maintain T and B cells in the inflamed meninges and in
the cortex of MS.
Conclusions
Our findings indicate that intrathecally synthesized IgG
are produced by PCs that enter the CNS from the per-
ipheral blood at a given time and are locally retained as
long-term PCs. A role for FLS as source of intrathecal
IgG in early disease phases is not supported by our
observations on CXCL13.
In our study, CXCL13 identifies a subgroup of MS
patients characterized by the early evidence of cortical
thinning, further suggesting a role for this chemokine as
marker of disease severity.
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